NO943874L - Behandling av resistant neoplasma - Google Patents

Behandling av resistant neoplasma

Info

Publication number: NO943874L
Authority: NO; Norway
Prior art keywords: treatment; chem; resistant neoplasm; neoplasm; resistant
Prior art date: 1993-10-15

Application number

NO943874A

Other languages

English (en)

Norwegian (no)

Other versions

NO943874D0 (no

Inventor

Srinivasan Chandrasekhar

Anne Hollins Dantzig

Robert Lee Shepard

James Jacob Starling

Mark Alan Winter

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-10-15

Filing date

1994-10-13

Publication date

1995-04-18

1994-10-13 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

1994-10-13 Publication of NO943874D0 publication Critical patent/NO943874D0/no

1995-04-18 Publication of NO943874L publication Critical patent/NO943874L/no

Links

206010028980 Neoplasm Diseases 0.000 title abstract 2
208000035269 cancer or benign tumor Diseases 0.000 title 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
229910052739 hydrogen Inorganic materials 0.000 abstract 1
239000001257 hydrogen Substances 0.000 abstract 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 abstract 1
-1 pyrrolidino, hexamethyleneimino Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000012453 solvate Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)
Steroid Compounds (AREA)

NO943874A 1993-10-15 1994-10-13 Behandling av resistant neoplasma NO943874L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US13767893A	1993-10-15	1993-10-15

Publications (2)

Publication Number	Publication Date
NO943874D0 NO943874D0 (no)	1994-10-13
NO943874L true NO943874L (no)	1995-04-18

Family

ID=22478575

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO943874A NO943874L (no)	1993-10-15	1994-10-13	Behandling av resistant neoplasma

Country Status (17)

Country	Link
EP (1)	EP0652004B1 (fr)
JP (1)	JPH07149638A (fr)
KR (1)	KR950010891A (fr)
CN (1)	CN1108094A (fr)
AT (1)	ATE220323T1 (fr)
AU (1)	AU670518B2 (fr)
CA (1)	CA2118096A1 (fr)
CZ (1)	CZ253694A3 (fr)
DE (1)	DE69430940T2 (fr)
DK (1)	DK0652004T3 (fr)
ES (1)	ES2179063T3 (fr)
HU (1)	HUT71237A (fr)
IL (1)	IL111287A0 (fr)
NO (1)	NO943874L (fr)
PT (1)	PT652004E (fr)
RU (1)	RU94037233A (fr)
ZA (1)	ZA948025B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5441964A (en) *	1993-10-15	1995-08-15	Eli Lilly And Company	Methods for inhibiting bone loss using substituted benzothiophene
MX9701359A (es) *	1994-08-22	1997-05-31	Lilly Co Eli	Metodos para la inhibicion de la hiperplasia endometrial primaria.
AU688112B2 (en) *	1994-08-22	1998-03-05	Eli Lilly And Company	Methods of inhibiting endometrial cancer
EP0777472A2 (fr)	1994-08-31	1997-06-11	Eli Lilly And Company	Procedes d'identification et de traitement de tumeurs resistantes
IL115582A0 (en) *	1994-10-14	1996-01-19	Lilly Co Eli	Methods for treating resistant tumors
ZA961564B (en) *	1995-02-28	1997-08-27	Lilly Co Eli	Methods of inhibiting ovarian cancer.
US5843974A (en) *	1995-06-06	1998-12-01	Eli Lilly And Company	Methods of inhibiting melanoma using Benzothiophenes as cytotoxic agents per se
WO1997017069A1 (fr) *	1995-11-07	1997-05-15	Eli Lilly And Company	Procedes pour traiter des tumeurs resistantes
ID15917A (id) *	1996-01-29	1997-08-21	Lilly Co Eli	Metode untuk menghambat tumor usus besar
US5670523A (en) *	1996-01-29	1997-09-23	Eli Lilly And Company	Methods of inhibiting musculoaponeurotic fibromatoses (desmoid tumors)
PL328127A1 (en) *	1996-01-29	1999-01-18	Lilly Co Eli	Methods of inhibiting aponeurotic muscular fibromatosis
IL120266A (en)	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
TW442286B (en) *	1996-02-28	2001-06-23	Pfizer	New therapeutic uses of estrogen agonists
CZ300261B6 (cs) *	1996-10-30	2009-04-01	Eli Lilly And Company	Použití hydrochloridové soli raloxifenu pro prípravu léciva pro prevenci rakoviny prsu
US6025373A (en) *	1997-04-22	2000-02-15	Eli Lilly And Company	Methods for reducing fibrinogen
WO2002089801A1 (fr) *	2001-05-10	2002-11-14	Cedars Sinai Medical Center	Utilisation de benzothiophenes pour traiter et prevenir le cancer de la prostate
US7425565B2 (en)	2002-05-09	2008-09-16	Cedars-Sinai Medical Center	Use of benzothiopenes to treat and prevent prostate cancer
FR2873692B1 (fr) *	2004-07-29	2006-12-01	Univ Claude Bernard Lyon	COMPOSITIONS CONTENANT, EN ASSOCIATION AVEC UN AGENT ANTIMICROBIEN, UN COMPOSE THIOPHENIQUE OU BENZOTHIOPHENIQUE DE FORMULE(I)PRESENTANT UNE ACTIVITE INHIBITRICE DE POMPE NorA

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4133814A (en) *	1975-10-28	1979-01-09	Eli Lilly And Company	2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents
US4418068A (en) *	1981-04-03	1983-11-29	Eli Lilly And Company	Antiestrogenic and antiandrugenic benzothiophenes

1994
- 1994-10-13 CZ CZ942536A patent/CZ253694A3/cs unknown
- 1994-10-13 AT AT94307527T patent/ATE220323T1/de not_active IP Right Cessation
- 1994-10-13 NO NO943874A patent/NO943874L/no unknown
- 1994-10-13 CN CN94117124A patent/CN1108094A/zh active Pending
- 1994-10-13 DK DK94307527T patent/DK0652004T3/da active
- 1994-10-13 JP JP6247763A patent/JPH07149638A/ja not_active Withdrawn
- 1994-10-13 CA CA002118096A patent/CA2118096A1/fr not_active Abandoned
- 1994-10-13 ZA ZA948025A patent/ZA948025B/xx unknown
- 1994-10-13 KR KR1019940026162A patent/KR950010891A/ko not_active Withdrawn
- 1994-10-13 EP EP94307527A patent/EP0652004B1/fr not_active Expired - Lifetime
- 1994-10-13 ES ES94307527T patent/ES2179063T3/es not_active Expired - Lifetime
- 1994-10-13 HU HU9402961A patent/HUT71237A/hu unknown
- 1994-10-13 PT PT94307527T patent/PT652004E/pt unknown
- 1994-10-13 IL IL11128794A patent/IL111287A0/xx unknown
- 1994-10-13 DE DE69430940T patent/DE69430940T2/de not_active Expired - Fee Related
- 1994-10-13 AU AU75786/94A patent/AU670518B2/en not_active Ceased
- 1994-10-13 RU RU94037233/14A patent/RU94037233A/ru unknown

Also Published As

Publication number	Publication date
EP0652004A1 (fr)	1995-05-10
RU94037233A (ru)	1996-08-27
DE69430940D1 (de)	2002-08-14
HUT71237A (en)	1995-11-28
ZA948025B (en)	1996-04-15
PT652004E (pt)	2002-10-31
CN1108094A (zh)	1995-09-13
HU9402961D0 (en)	1995-02-28
CA2118096A1 (fr)	1995-04-16
JPH07149638A (ja)	1995-06-13
NO943874D0 (no)	1994-10-13
DE69430940T2 (de)	2003-04-03
ES2179063T3 (es)	2003-01-16
AU670518B2 (en)	1996-07-18
AU7578694A (en)	1995-05-04
IL111287A0 (en)	1994-12-29
KR950010891A (ko)	1995-05-15
DK0652004T3 (da)	2002-09-02
CZ253694A3 (en)	1995-05-17
ATE220323T1 (de)	2002-07-15
EP0652004B1 (fr)	2002-07-10

Publication	Publication Date	Title
DE69402173D1 (de)	1997-04-24	Hemmung von Thrombin
NO943879L (no)	1995-04-18	Hemming av endometriose
NO943874D0 (no)	1994-10-13	Behandling av resistant neoplasma
NO943878L (no)	1995-04-18	Hemming av uterinfibrose
DE69402165D1 (de)	1997-04-24	Hemmung von Seborrhoe und Akne
NO943873D0 (no)	1994-10-13	Hemming av bruskdegradering
ATE203406T1 (de)	2001-08-15	Hemmung von hirsutismus und alopecia bei frauen
MX9702861A (es)	1997-07-31	Metodo para inhibir las condiciones asociadas con la bradicinina.